These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32329404)

  • 21. Hospital Pharmacy in the multidisciplinary team of COVID inpatient units.
    Gil-Navarro MV; Luque-Márquez R
    Farm Hosp; 2020 Jun; 44(7):40-42. PubMed ID: 32533669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Shortages and the Defense Production Act.
    Raunig BL; Kesselheim AS; Darrow JJ
    Am J Public Health; 2020 Oct; 110(10):1504-1505. PubMed ID: 32903085
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical care: pharmacy's mission for the 1990s.
    Penna RP
    Am J Hosp Pharm; 1990 Mar; 47(3):543-9. PubMed ID: 2316539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacy practice in emergency response during the COVID-19 pandemic: Lessons from Australia.
    Parajuli DR; Khanal S; Wechkunanukul KH; Ghimire S; Poudel A
    Res Social Adm Pharm; 2022 Aug; 18(8):3453-3462. PubMed ID: 34810136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How price-gouging regulation undermined COVID-19 mitigation: county-level evidence of unintended consequences.
    Chakraborti R; Roberts G
    Public Choice; 2023 Apr; ():1-33. PubMed ID: 37360988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dirt cheap and without prescription: how susceptible are young US consumers to purchasing drugs from rogue internet pharmacies?
    Ivanitskaya L; Brookins-Fisher J; O Boyle I; Vibbert D; Erofeev D; Fulton L
    J Med Internet Res; 2010 Apr; 12(2):e11. PubMed ID: 20439253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are there positive lessons for Italy's NHS resulting from the Covid-19 pandemic?
    Baldino G; Argo A; Stassi C; Zerbo S; Ventura Spagnolo E
    Med Leg J; 2020 Jul; 88(2):84-86. PubMed ID: 32419599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HOSPITAL PHARMACY'S RESPONSIBILITIES TO SPONSORS OF INVESTIGATIONAL DRUGS.
    SKOLAUT MW
    Hosp Top; 1965 Aug; 43():91-5. PubMed ID: 14345620
    [No Abstract]   [Full Text] [Related]  

  • 30. LEGAL CHARACTERISTICS OF PHARMACEUTICAL ACTIVITY UNDER THE EMERGENCY CONDITIONS: PANDEMIC AND WAR.
    Pashkov V; Soloviov O; Harkusha A
    Wiad Lek; 2022; 75(9 pt 2):2286-2292. PubMed ID: 36378710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacy administration and pharmaceutical care practice in a module hospital during the COVID-19 epidemic.
    Hua X; Gu M; Zeng F; Hu H; Zhou T; Zhang Y; Shi C
    J Am Pharm Assoc (2003); 2020; 60(3):431-438.e1. PubMed ID: 32336673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hospital pharmacist experience in a multidisciplinary team in special care settings.
    Santolaya-Perrin R; García-Martín Á; Carrero-Fernández A; Torres-Santos-Olmo R
    Farm Hosp; 2020 Jun; 44(7):36-39. PubMed ID: 32533668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic.
    Cundell T; Guilfoyle D; Kreil TR; Sawant A
    PDA J Pharm Sci Technol; 2020; 74(4):468-494. PubMed ID: 32467176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prescription reimbursement methodologies in Japan and the United States.
    Akaho E; MacLaughlin EJ; Takeuchi Y
    J Am Pharm Assoc (2003); 2003; 43(4):519-26. PubMed ID: 12952317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. South African competition policy on excessive pricing and its relation to price gouging during the COVID-19 disaster period.
    Boshoff WH
    S Afr J Econ; 2021 Mar; 89(1):112-140. PubMed ID: 33041376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The health scare of COVID-19 amidst pandemics and the immune-related pharmaceutical products spillovers in the USA.
    Alola AA; Olowu FB
    Environ Sci Pollut Res Int; 2020 Dec; 27(36):45949-45956. PubMed ID: 33064278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Navigating regulatory statutes during the COVID-19 pandemic.
    Murray KL; Burgess LH; Miller KM
    Am J Health Syst Pharm; 2020 Aug; 77(16):1275-1276. PubMed ID: 32406905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.